Methods and compositions for preventing and treating atherosclerosis
CA2806606A1
Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction comprising an apolipoprotein peptide/phospholipid complex
US2010330683A1
Method for quantifying oxidative stress caused by different biological pathways
CA2788223A1
Method for the prevention and treatment of diastolic dysfunction employing an apolipoproteina1 (apoa1) mimetic peptide/phospholipid complex
WO2009152619A1
A method of detecting a subject at risk of, or having, an indication associated with coronary artery disease
WO2009030051A1
Quantification of changes in the degree of order of cellular and viral membranes and applications to diagnosis, treatment and drug screening
US2008166717A1
Angiopoietin-like 2 as a biomarker of vascular endothelial cell abnormal function and senescence
MX2008015337A
Method and compound for the treatment of valvular stenosis.
CA2672322A1
Method for detecting a biomarker of oxidative stress in a biological sample
CN101379396A
Method for detecting a biomarker of oxidative stress in a biological sample
CA2550417A1
Method for maintaining cerebral hemispheric oxygen saturation during surgery
WO2006039806A1
Depression of herg k+ channel function in mammalian cells and applications to the control of cancer cells division
EP1749026A1
Labelled adrenomedullin derivatives and their use for imaging and therapy
WO2006047849A1
Methods of identifying compounds that regulate acetylcholine-dependent potassium current in cardiac cells for treating atrial fibrillation.
US7430309B2
Computation of a geometric parameter of a cardiac chamber from a cardiac tomography data set
CA2537104A1
Catherter for measuring an intraventricular pressure and method of using same
WO2005021006A1
Method and substance for facilitating weaning, reducing morbidity and reducing mortality in cardiac surgeries involving extra-corporal circulation
EP1613306A1
Decreasing the incidence of atrial fibrillation (af) in patients with left ventricular dysfunction with ace inhibitors or angiotensin ii receptor antagonists
AU2002351618A8
An antisense strategy to modulate estrogen receptor response (er. alpha. and/or er. beta.)
CA2460501A1
Method for identification and visualization of atrial tissue
